Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Ensuring Study Staff Role Clarity – V 2.0

Posted on By

BA-BE Studies: SOP for Ensuring Study Staff Role Clarity – V 2.0

Standard Operating Procedure to Ensure Study Staff Role Clarity in BA/BE Clinical Trials

Department BA-BE Studies
SOP No. SOP/BA-BE/145/2025
Supersedes SOP/BA-BE/145/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To ensure clear definition, documentation, communication, and adherence to roles and responsibilities of all personnel involved in BA/BE clinical trials, thereby promoting accountability, reducing errors, and supporting GCP compliance.

2. Scope

This SOP applies to all clinical, bioanalytical, QA, data management, pharmacy, and administrative staff associated with the conduct of BA/BE studies at the clinical site or sponsor organization.

3. Responsibilities

  • Clinical Operations Manager: Oversees role allocation and approval of role responsibility matrices.
  • Principal Investigator (PI): Ensures that responsibilities are aligned with protocol requirements and regulatory expectations.
  • HR/Training Coordinator: Maintains training records and ensures all staff are aware of their designated responsibilities.
  • Department Heads: Validate role-specific SOPs and clarify team deliverables.
See also  BA-BE Studies: SOP for Pre-Submission Meeting with Regulatory Authorities - V 2.0

4. Accountability

The Clinical Research Director or Head of Clinical Operations is accountable for ensuring effective implementation of this SOP and resolution of any role-based conflict or ambiguity.

5. Procedure

5.1 Role Identification and Allocation

  1. Prepare a Role and Responsibility Matrix (Annexure-1) prior to study initiation based on protocol tasks, site needs, and ICH-GCP guidelines.
  2. Define key positions including but not limited to:
    • Principal Investigator (PI)
    • Sub-Investigator
    • Study Coordinator
    • Pharmacist
    • Phlebotomist
    • Bioanalytical Scientist
    • Quality Assurance Officer
  3. Each role should have defined primary and secondary responsibilities documented and approved by the Department Head.

5.2 Communication of Roles

  1. Conduct a Study Kickoff Meeting where the role matrix is presented and explained to all staff.
  2. Circulate signed copies of the matrix to all team members and post it in the study control room.
  3. Staff must acknowledge their understanding of roles by signing the Role Acknowledgment Log (Annexure-2).

5.3 Role-Based Training and Competency

  1. Assign training modules based on specific roles using applicable SOPs and study protocol sections.
  2. Training must be documented in the Staff Training Log (Annexure-3) with trainer signature and date.
  3. Conduct assessments, if required, for critical roles (e.g., dosing, sample processing, SAE reporting).
See also  BA-BE Studies: SOP for Handling Cold Chain Breaches During Sample Storage - V 2.0

5.4 Handling Role Ambiguities or Overlaps

  1. In case of ambiguity:
    • Raise a formal clarification request to the Clinical Operations Manager.
    • Update matrix and communicate revised roles to all stakeholders.
  2. In case of staff unavailability, alternate persons should be cross-trained and designated in the matrix.

5.5 Monitoring and Compliance

  1. QA team to verify role compliance during study audits and monitoring visits.
  2. Any observed deviation from designated roles must be documented and addressed via CAPA.
  3. Updates to roles or reassignment must be approved by PI and documented in an updated matrix version.

5.6 Documentation and Archiving

  1. All role-related documents must be filed in the study-specific Trial Master File (TMF).
  2. Archived records must be retained for at least 5 years post-study or as per regulatory requirements.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • PI: Principal Investigator
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • TMF: Trial Master File

7. Documents

  1. Role and Responsibility Matrix – Annexure-1
  2. Role Acknowledgment Log – Annexure-2
  3. Staff Training Log – Annexure-3
See also  BA-BE Studies: SOP for Third-Party Vendor Qualification (Labs, Courier) - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Indian GCP Guidelines
  • Company Training Policy and HR SOPs

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Role and Responsibility Matrix

Role Primary Responsibilities Backup Staff
Pharmacist IMP receipt, labeling, storage, accountability Sunita Reddy
PI Subject safety, protocol compliance Dr. Vinay Pawar

Annexure-2: Role Acknowledgment Log

Name Designation Role Signature Date
Rajesh Kumar Study Coordinator Subject randomization, CRF updates Signed 15/04/2025

Annexure-3: Staff Training Log

Staff Name Role Training Topic Date Trainer Remarks
Ajay Verma Phlebotomist PK sample collection 14/04/2025 QA Officer Trained

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release Role management SOP introduction QA Head
17/04/2025 2.0 Expanded procedure and annexures for training and role sign-off Audit preparation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Maintaining Equipment Logbooks in Aerosol Manufacturing – V 2.0
Next Post: Creams: SOP for Ensuring Data Integrity in QC Documentation – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version